References
- Terpos E, Christoulas D, Gavriatopoulou M. Biology and treatment of myeloma related bone disease. Metabolism 2018; 80: 80–90. doi: 10.1016/j.metabol.2017.11.012
- Hansford BG, Silbermann R. Advanced imaging of multiple myeloma bone disease. Front Endocrinol 2018; 9: 436. doi: 10.3389/fendo.2018.00436
- Duvauferrier R, Valence M, Patrat-Delon S, Brillet E, Niederberger E, Marchand A, et al. Current role of CT and whole body MRI in multiple myeloma. Diagn Interv Imaging 2013; 94: 169–83. doi: 10.1016/j.diii.2012.12.001
- Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009; 23: 1545–56. doi: 10.1038/leu.2009.89
- Moulopoulos LA, Gika D, Anagnostopoulos A, Delasalle K, Weber D, Alexanian R, et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol 2005; 16:1824–8. doi: 10.1093/annonc/mdi362
- Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, et al. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology 2019; 291: 5–13. doi: 10.1148/radiol.2019181949
- Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 2015; 33: 657–64. doi: 10.1200/JCO.2014.57.9961
- Messiou C, Kaiser M. Whole body diffusion weighted MRI – a new view of myeloma. Br J Haematol 2015; 171: 29–37. doi: 10.1111/bjh.13509
- Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, et al. NCCN Guidelines Insights: multiple myeloma, Version 3.2018. J Natl Compr Canc Netw 2018; 16: 11–20. doi: 10.6004/jnccn.2018.0002
- Dutoit JC, Verstraete KL. MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings. Insights Imaging 2016; 7: 553–569. doi: 10.1007/s13244-016-0492-7
- Lecouvet FE, Vande Berg BC, Michaux L, Malghem J, Maldague BE, Jamart J, et al. Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging. Radiology 1998; 209: 653–60. doi: 10.1148/radiology.209.3.9844655
- Baur-Melnyk A, Buhmann S, Dürr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 2005; 55: 56–63. doi: 10.1016/j.ejrad.2005.01.017
- Moulopoulos LA, Varma DG, Dimopoulos MA, Leeds NE, Kim EE, Johnston DA, et al. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 1992; 185: 833–40. doi: 10.1148/radiology.185.3.1438772
- Dutoit JC, Vanderkerken MA, Anthonissen J, Dochy F, Verstraete KL. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma. Eur Radiol 2014; 24: 2754–65. doi: 10.1007/s00330-014-3324-5
- Padhani AR, van Ree K, Collins DJ, D’Sa S, Makris A. Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI. AJR Am J Roentgenol 2013; 200: 163–70. doi: 10.2214/AJR.11.8185
- Zhang Y, Xiong X, Fu Z, Dai H, Yao F, Liu D, et al. Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy: a large single-center cohort study. Eur J Radiol 2019; 120: 108695. doi: 10.1016/j.ejrad.2019.108695
- Shaughnessy JD, Jr., Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276–84. doi: 10.1182/blood-2006-07-038430
- Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, et al. Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era. Hematol Rep 2017; 9: 6887. doi: 10.4081/hr.2017.6887
- Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–8. doi: 10.1038/leu.2013.313
- Younes M, Hachfi H, Hammouda F, Younes K, Ben Hammouda S, Jguirim M, et al. [Survival prognosis factors in multiple myeloma]. [French]. Tunis Med 2014; 92: 399–405. PMID: 25741841
- Yamasaki S, Kohno K, Kadowaki M, Takase K, Okamura S. Dose-adjusted lenalidomide combined with low-dose dexamethasone rescues older patients with bortezomib-resistant multiple myeloma. Intern Med 2015; 54: 1711–5. doi: 10.2169/internalmedicine.54.4075
- Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–20. doi: 10.1200/JCO.2005.04.242
- Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from International Myeloma Working Group. J Clin Oncol 2015; 33: 2863–9. doi: 10.1200/JCO.2015.61.2267
- Barlogie B, Bolejack V, Schell M, Crowley J. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol 2011; 90: 423–8. doi: 10.1007/s00277-010-1130-y
- Colović M, Janković G, Suvajdzić N, Milić N, Dordević V, Janković S. Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol 2008; 25: 154–60. doi: 10.1007/s12032-007-9011-5
- Perez-Andres M, Almeida J, Martin-Ayuso M, De Las Heras N, Moro MJ, Martin-Nuñez G, et al. Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease. Int J Cancer 2009; 124: 367–75. doi: 10.1002/ijc.23941
- Tian C, Wang L, Wu L, Zhu L, Xu W, Ye Z, et al. Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis. Biosci Rep 2018; 38: BSR20171697. doi: 10.1042/BSR20171697
- Baur A, Stäbler A, Nagel D, Lamerz R, Bartl R, Hiller E, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002; 95: 1334–45. doi: 10.1002/cncr.10818
- Baur A, Stäbler A, Bartl R, Lamerz R, Reiser M. [Infiltration patterns of plasmacytomas in magnetic resonance tomography]. Rofo 1996; 164: 457–63. doi: 10.1055/s-2007-1015689